## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73**
- Source: Simply Wall Street | 20251202T193951 | Neutral | Relevance: 99%
- AbbVie (NYSE:ABBV) announced an increase in its dividend to $1.73 per share, payable on February 17th, with a yield of 3.1%. While cash flow covers the dividend despite recent profit declines, the company's dividend growth potential is considered shaky due to a 22% annual EPS decline over the past five years, though earnings are predicted to rise in the next year. Investors should be aware of potential risks despite the consistent dividend policy.

**2. AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73**
- Source: Simply Wall Street | 20251202T191409 | Somewhat-Bullish | Relevance: 99%
- AbbVie Inc. (NYSE:ABBV) has announced an increase in its dividend to $1.73, payable on February 17th, with the dividend yield approximately matching the industry average at 3.1%. While future dividend projections appear well-covered by cash flow despite past profit deficits, the company's EPS has declined by 22% per year over the last five years, raising concerns about long-term dividend sustainability even with predicted earnings growth in the next year. Investors should consider these factors alongside the company's solid track record of dividend growth.

**3. AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyriziâ€™s Canada Win, Medicare Cuts and Fresh Analyst Targets**
- Source: ts2.tech | 20251130T225044 | Somewhat-Bullish | Relevance: 98%
- AbbVie (ABBV) heads into December 1, 2025, with its stock trading near $227, reflecting a strong year but a recent dip due to Medicare pricing news. Key developments include a significant reimbursement win in Canada for Skyrizi, U.S. Medicare price cuts affecting Linzess and Vraylar, and ongoing analyst evaluation. The company's Q3 2025 results showed robust immunology growth, raised EPS guidance, and a dividend increase, despite some portfolio softness and policy risks.

**4. AbbVie (NYSE: ABBV) highlights ASH 2025 advances in T-cell engagers, BCL-2 and ADCs**
- Source: Stock Titan | 20251202T131500 | Bullish | Relevance: 98%
- AbbVie will present new data at ASH 2025 showcasing advances in T-cell engagers, BCL-2 inhibitors, and Antibody-Drug Conjugates for various blood cancers. Key highlights include epcoritamab's success in follicular lymphoma, venetoclax regimens in CLL, and promising early-phase data for etentamig and PVEK in multiple myeloma and AML, respectively. The data demonstrates significant efficacy signals but also highlights safety considerations such as neutropenia and infections.

**5. AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook**
- Source: ts2.tech | 20251202T211913 | Bullish | Relevance: 98%
- This article provides an in-depth analysis of AbbVie (ABBV) stock as of December 2, 2025, highlighting its recent dividend hike, momentum in its oncology and migraine pipelines, and positive outlook for 2026. It covers the stock's price, valuation, dividend profile, recent Q3 2025 earnings, strategic mergers and acquisitions, and Wall Street analyst ratings, while also addressing key risks for investors.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (1 raises, avg +18%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $398.0B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.1 |
| YoY Growth | 34.0% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from -1.7% to -4.8% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.8pp (needs >3.0% for momentum thesis). Underperforming sector by 4.6pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.72), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.80% (CS: 6) | Weak |
| RSI_14 | 45.5 | Neutral |
| MACD Histogram | -0.72 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 0.986x | Below |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $224.37
- **Stop Loss:** $213.45 (4.9% risk)
- **Target:** $235.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 91
- **Position Value:** $20,417.67
- **Portfolio %:** 20.42%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*